Chemotherapy-induced cardiotoxicity in cancer patients: an observational study at an Oncology reference hospital from southeastern Brazil
Authors:
Open Access
- 1 January 2026
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista Latino-Americana de Enfermagem
- Vol. 34, e4774
Abstract
Objective: to assess the clinical, inflammatory and electrocardiographic profile of cancer patients undergoing the Pre-chemotherapy phase, with the purpose of early identifying cardiovascular toxicity indicative signs. Method: an observational and cross-sectional study, conducted between November2022 and December2023 with adult cancer patients in stagesI toIII treated at a hospital from southern Brazil. Sociodemographic, clinical and tumor-related data were collected, in addition to laboratory and electrocardiographic tests performed before the first chemotherapy infusion. Descriptive analyses were carried out in the Rsoftware. Results: the participants were 84 patients, mostly women (72.6%) with breast cancer diagnoses(57.1%). Prevalence of systemic inflammation was verified, with high C-reactive protein in 35.7% and increased neutrophil-lymphocyte and platelet-lymphocyte ratios in 23.5% and 27.2%, respectively. A significant association was observed between high Body Mass Index and T-wave alterations (p=0.005). Although 10 patients presented prolonged corrected QT intervals, no other statistically significant associations were identified. Conclusion: the pre-chemotherapy phase revealed relevant inflammatory and electrocardiographic alterations, even in the absence of installed cardiotoxicity. The findings reinforce the importance of baseline cardiovascular evaluations and of multi-professional follow-up in Cardio-Oncology, especially for patients with modifiable risk factors. Longitudinal studies are recommended to elucidate the clinical and prognostic evolution of these alterations.Keywords
This publication has 53 references indexed in Scilit:
- Obesity: The Perfect Storm for Heart FailureESC Heart Failure, 2024
- A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic StrategiesCurrent Treatment Options in Oncology, 2024
- Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic MechanismCurrent Cardiology Reports, 2023
- High neutrophil‐to‐lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracyclineClinical Cardiology, 2023
- C‐reactive protein trajectories and the risk of all cancer types: A prospective cohort studyInternational Journal of Cancer, 2022
- Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic ApproachesCardiovascular Toxicology, 2022
- Chemotherapy-Induced Arrhythmia – Underrecognized and UndertreatedThe American Journal of Medicine, 2021
- Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- The Role of Biomarkers in Cardio-OncologyJournal of Cardiovascular Translational Research, 2020
- Anthracycline Chemotherapy and CardiotoxicityCardiovascular Drugs and Therapy, 2017